$Letter to the editor: effects of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer—a prospective observation study$

Letter to the editor: effects of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer—a prospective observation study

Saved in:

Bibliographic Details
Main Author:	Bi-Cheng Wang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-02-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/2/e011678.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study
by: Jing Wang, et al.
Published: (2025-01-01)

Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
by: Yanrong Wang, et al.
Published: (2025-03-01)

Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial
by: Rui Liu, et al.
Published: (2025-02-01)

Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview
by: Yejie Xie, et al.
Published: (2025-02-01)

Raltitrexed, S-1 and fruquintinib (RSF) in the treatment of refractory metastatic colorectal cancer: study protocol for a multicenter, prospective, single-arm, phase II trial
by: Weibing Leng, et al.
Published: (2025-02-01)

Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial
by: Xiangyu Meng, et al.
Published: (2025-07-01)

Efficacy and safety of immunotherapy combined with targeted therapy and chemotherapy in third-line treatment of microsatellite stable metastatic colorectal cancer
by: ZHAO Wensi, et al.
Published: (2025-07-01)

Effect of prognostic nutritional index on laboratory parameters and survival in metastatic colorectal cancer patients treated with fruquintinib: a retrospective study
by: Zeng Wang, et al.
Published: (2024-11-01)

Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
by: Marion Thibaudin, et al.
Published: (2023-12-01)

Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
by: Bi-Cheng Wang
Published: (2025-03-01)

Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer
by: Luís Nunes, et al.
Published: (2024-11-01)

The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies
by: Fan Yang, et al.
Published: (2025-05-01)

Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer
by: Jing Liu, et al.
Published: (2025-07-01)

Identification of candidate driver genes in common focal chromosomal aberrations of microsatellite stable colorectal cancer.
by: George J Burghel, et al.
Published: (2013-01-01)

The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study
by: Yao Wang, et al.
Published: (2025-07-01)

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
by: Matthew Burge, et al.
Published: (2023-01-01)

Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma
by: Jianhua Liu, et al.
Published: (2018-01-01)

Correction: The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study
by: Frontiers Production Office
Published: (2025-08-01)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
by: Christelle de La Fouchardière, et al.
Published: (2020-10-01)

The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma
by: Chenglong Zhao, et al.
Published: (2025-06-01)

Letters to the Editor
Published: (2011-09-01)

Letters to the Editor
by: Ricardo Baroudi, et al.

Letter to the Editor
by: Margaret M Kelly, et al.
Published: (2010-01-01)

Letters to the Editor
Published: (1999-01-01)

Letter to the Editor
by: Warren Teel, et al.
Published: (2010-01-01)

Letters to the Editor
by: Miklos Sebeszta, et al.
Published: (2014-01-01)

Letter to the Editor
by: S. A. Кurbatov
Published: (2017-09-01)

Letters to the Editor
by: S.K. Soniyi, et al.
Published: (2003-06-01)

Letters to the Editor
by: W.F.J. Rarthgeber, et al.
Published: (2003-07-01)

Letters to the Editor
by: Ian Couper
Published: (2004-03-01)

Letters to the Editor
by: Sa'ad Lahri, et al.
Published: (2004-05-01)

Letters to the Editor
by: O. A. Dolina
Published: (2008-08-01)

Letters to the Editor
by: Alison M. Kerr, et al.
Published: (1991-01-01)

Letter to the Editor
by: Uei Pua
Published: (2011-01-01)

Editor's letter
by: V G Barskova, et al.
Published: (2011-06-01)

Letter to the Editor
by: Sandra C Dorman, et al.
Published: (2010-01-01)

Letters to the Editor
by: Sergio M Borgia
Published: (2015-01-01)

Letter to the editors
by: Shigui Ruan
Published: (2008-11-01)

Editor’s Letter
by: José Sánchez Gutiérrez
Published: (2024-09-01)

Letter to editor
by: R. Mungmungpuntipantip, et al.
Published: (2021-03-01)